Nycomed to accelerate expansion in China
- Details
- Category: Nycomed
Nycomed announced that it is significantly expanding its presence in China through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma Co., Ltd. (Techpool), a fast-growing Chinese bio-pharmaceutical company based in Guangdong.
Novartis drug Afinitor® approved by FDA
- Details
- Category: Novartis
Novartis announced, that the US Food and Drug Administration (FDA) has approved Afinitor® (everolimus) tablets for patients with subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS), who require therapeutic intervention but are not candidates for curative surgical resection[2].
GlaxoSmithKline receives approval in Japan for two medicines: Revolade and Xyzal
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that it has received approval in Japan from the Ministry of Health, Labour and Welfare for Revolade (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP), and for Xyzal (levocetirizine dihydrochloride), the first new anti-histamine to be made available in Japan for eight years.
Sanofi-aventis to Acquire BMP Sunstone creating a Strong Consumer Healthcare Platform in China
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and BMP Sunstone Corporation (NASDAQ: BJGP) have entered into a definitive agreement under which sanofi-aventis is to acquire all outstanding shares of BMP Sunstone for cash consideration of USD 10 per share, or a total of approximately USD 520.6 million on a fully diluted basis.
Merck KGaA Sells Théramex To Teva for EUR 265 million
- Details
- Category: Merck Group
Merck KGaA announced that it will sell Théramex, its Monaco-based pharmaceutical company specialized in women's health and gynecology, to Teva. Merck and Teva have signed an agreement whereby Teva will acquire all Théramex operations including 100% of the shares of Théramex S.A.M of Monaco and Théramex S.p.A. of Italy for a consideration of EUR 265 million.
Bayer lifts sales and earnings again
- Details
- Category: Bayer
Sales of the Bayer Group rose by 16.1 percent in the third quarter, to EUR 8,581 million (Q3 2009: EUR 7,392 million). Adjusted for currency and portfolio effects, business expanded by 8.4 percent. Earnings before interest, taxes, depreciation and amortization (EBITDA) - before special items - improved by 10.5 percent to EUR 1,656 million (Q3 2009: EUR 1,499 million).
Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced the publication of data showing that 57 percent of ALK-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib (PF-02341066), an investigational oral anaplastic lymphoma kinase (ALK) inhibitor, had either a complete (one patient) or partial (46 patients) response to treatment.
More Pharma News ...
- Bristol-Myers Squibb Third Quarter Featured Solid Operating Performance
- Merck KGaA Profit After Tax Jumps 45% to EUR 215 Million
- AstraZeneca initiates phase IIB study for AZD9773
- FDA approves Herceptin for HER2-positive metastatic stomach cancer
- Novartis delivers excellent performance in third quarter
- US FDA Approves Pradaxa® (dabigatran etexilate)
- Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil